中 EN   
维昇药业公众号
维昇药业视频号
  
COOKIES Policy
We use cookies to improve your browsing experience and help us improve our service by understanding your habits as you use the website. If you decline to accept cookies from us, please do so through your browser settings. Please note that if you disable cookies, you may not be able to use all functions of the website. You can learn more about how we use cookies by visiting our Privacy Policy. When you click 'I agree', you acknowledge that you have fully read and agreed to our Privacy Policy.
COOKIES Policy
I agree
About Us
Science & Pipeline
Disease Area
Investors
Responsibility
Careers
News
Innovation Brings Light to LifeAccelerating the development of endocrinology treatment with
the world’s most advanced technologies
Company Overview Vision and Mission Leadership Contact Us
Pipeline TransCon Tech Lonapegsomatropin Palopegteriparatide TransCon CNP
Stock Information InformationDisclosure Corporate Governance IR Contacts
Navepegritide (TransCon CNP)
Navepegritide (TransCon CNP) is a long-acting prodrug of C-type natriuretic peptide, or CNP, in development for the treatment of achondroplasia, or ACH, in children, which is the first achondroplasia disease-modifying therapy in clinical development in China to date. It is designed to provide continuous CNP exposure which inhibits the effect of constitutive fibroblast growth factor receptor 3 (FGFR3) over-activation 24 hours a day, aiming to promote bone growth and ameliorate and prevent complications and comorbidities of ACH.

China Phase 2 clinical trial of TransCon CNP is ongoing, whose double-blind period was completed and met its primary endpoint in November 2023. Navepegritide (TransCon CNP) was granted orphan drug recognition for the treatment of achondroplasia by U.S. Food & Drug Administration (FDA) in February 2019 and European Commission (EC) in August 2020.
About Us
Company Overview
Vision and Mission
Leadership
Contact Us
Science & Pipeline
Pipeline
TransCon Tech
Lonapegsomatropin
Palopegteriparatide
TransCon CNP
Disease Area
Growth Hormone Deficiency
Hypoparathyroidism
Achondroplasia
Investors
Stock Information
InformationDisclosure
Corporate Governance
IR Contacts
Responsibility
Careers
Work in VISEN
News
News
Partner News
Copyright Declaration | Privacy Policy | Copyright VISEN Pharmaceuticals (Shanghai) Co., Ltd 沪ICP备19045055号-1

沪公网安备 31010602007056号


This webpage is not a commercial advertisement. Only for healthcare professionals to read and reference.